1017 related articles for article (PubMed ID: 7475321)
41. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design.
Zhan P; Chen X; Li D; Fang Z; De Clercq E; Liu X
Med Res Rev; 2013 Jun; 33 Suppl 1():E1-72. PubMed ID: 21523792
[TBL] [Abstract][Full Text] [Related]
42. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.
Buckheit RW; Watson K; Fliakas-Boltz V; Russell J; Loftus TL; Osterling MC; Turpin JA; Pallansch LA; White EL; Lee JW; Lee SH; Oh JW; Kwon HS; Chung SG; Cho EH
Antimicrob Agents Chemother; 2001 Feb; 45(2):393-400. PubMed ID: 11158731
[TBL] [Abstract][Full Text] [Related]
43. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase.
Young SD; Britcher SF; Tran LO; Payne LS; Lumma WC; Lyle TA; Huff JR; Anderson PS; Olsen DB; Carroll SS
Antimicrob Agents Chemother; 1995 Dec; 39(12):2602-5. PubMed ID: 8592986
[TBL] [Abstract][Full Text] [Related]
44. Anti-human immunodeficiency virus (HIV) activities of halogenated gomisin J derivatives, new nonnucleoside inhibitors of HIV type 1 reverse transcriptase.
Fujihashi T; Hara H; Sakata T; Mori K; Higuchi H; Tanaka A; Kaji H; Kaji A
Antimicrob Agents Chemother; 1995 Sep; 39(9):2000-7. PubMed ID: 8540706
[TBL] [Abstract][Full Text] [Related]
45. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Antiviral Res; 1998 Jun; 38(3):153-79. PubMed ID: 9754886
[TBL] [Abstract][Full Text] [Related]
46. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.
D'Cruz OJ; Uckun FM
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):329-50. PubMed ID: 17059165
[TBL] [Abstract][Full Text] [Related]
47. The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
Xu G; Micklatcher M; Silvestri MA; Hartman TL; Burrier J; Osterling MC; Wargo H; Turpin JA; Buckheit RW; Cushman M
J Med Chem; 2001 Nov; 44(24):4092-113. PubMed ID: 11708913
[TBL] [Abstract][Full Text] [Related]
48. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
Kim EY; Vrang L; Oberg B; Merigan TC
AIDS Res Hum Retroviruses; 2001 Mar; 17(5):401-7. PubMed ID: 11282008
[TBL] [Abstract][Full Text] [Related]
49. Selection and characterization of viruses resistant to the dual acting pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor IQP-0410.
Buckheit RW; Watson Buckheit K; Sturdevant CB; Buckheit RW
Antiviral Res; 2013 Nov; 100(2):382-91. PubMed ID: 24055450
[TBL] [Abstract][Full Text] [Related]
50. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV.
Witvrouw M; Pannecouque C; Van Laethem K; Desmyter J; De Clercq E; Vandamme AM
AIDS; 1999 Aug; 13(12):1477-83. PubMed ID: 10465070
[TBL] [Abstract][Full Text] [Related]
51. Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor.
Romines KR; Freeman GA; Schaller LT; Cowan JR; Gonzales SS; Tidwell JH; Andrews CW; Stammers DK; Hazen RJ; Ferris RG; Short SA; Chan JH; Boone LR
J Med Chem; 2006 Jan; 49(2):727-39. PubMed ID: 16420058
[TBL] [Abstract][Full Text] [Related]
52. Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
Boone LR
Curr Opin Investig Drugs; 2006 Feb; 7(2):128-35. PubMed ID: 16499282
[TBL] [Abstract][Full Text] [Related]
53. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Stup TL; Pyle CA; White EL; McMahon JB; Currens MJ; Boyd MR
Antiviral Res; 1995 Mar; 26(2):117-32. PubMed ID: 7541618
[TBL] [Abstract][Full Text] [Related]
54. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
Xu H
Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
[TBL] [Abstract][Full Text] [Related]
55. Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor.
Buckheit RW; Hollingshead MG; Germany-Decker J; White EL; McMahon JB; Allen LB; Ross LJ; Decker WD; Westbrook L; Shannon WM
Antiviral Res; 1993 Jul; 21(3):247-65. PubMed ID: 7692815
[TBL] [Abstract][Full Text] [Related]
56. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.
Mathez D; Schinazi RF; Liotta DC; Leibowitch J
Antimicrob Agents Chemother; 1993 Oct; 37(10):2206-11. PubMed ID: 7504908
[TBL] [Abstract][Full Text] [Related]
57. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
Zhang Z; Xu W; Koh YH; Shim JH; Girardet JL; Yeh LT; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2007 Feb; 51(2):429-37. PubMed ID: 17116677
[TBL] [Abstract][Full Text] [Related]
58. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.
Kleim JP; Rösner M; Winkler I; Paessens A; Kirsch R; Hsiou Y; Arnold E; Riess G
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):34-8. PubMed ID: 8552634
[TBL] [Abstract][Full Text] [Related]
59. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.
Buckheit RW; Snow MJ; Fliakas-Boltz V; Kinjerski TL; Russell JD; Pallansch LA; Brouwer WG; Yang SS
Antimicrob Agents Chemother; 1997 Apr; 41(4):831-7. PubMed ID: 9087499
[TBL] [Abstract][Full Text] [Related]
60. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
Balzarini J; Pelemans H; Karlsson A; De ClercQ E; Kleim JP
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):13152-7. PubMed ID: 8917560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
